We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Make Data Work for You in the Race To Manufacture Effective Vaccines
Industry Insight

It’s imperative that scientists and leaders in the COVID-19 vaccine development space have good data management practices to ensure the quality of data and to recue the time-to-market now, and in the future. In this article, we explore how to make data work for you when manufacturing an effective vaccine.

Read More

Accelerated Screen Identifies 25 Existing Drugs Capable of Disrupting SARS-CoV-2 Cell Entry
Industry Insight

A team from the National Center for Advancing Translational Sciences (NCATS) has screened existing drug compounds that have already passed through the entire drug development pipeline, to determine if any can disrupt the interaction between the SARS-CoV-2 spike protein and the host’s angiotensin converting enzyme 2 (ACE2) receptor.

Read More

Looking Beyond the Spike Protein for SARS-CoV-2 Vaccine Design
Industry Insight

Biotech company COVAXX is developing a COVID-19 vaccine using a multi-antigen peptide platform, which not only targets the infamous SARS-CoV-2 Spike (S) protein but also targets other parts of the virus to enhance the immune response. Technology Networks spoke with Mei Mei Hu, co-founder of COVAXX, to learn more about the vaccine platform and the preclinical data that has been obtained for UB-612.

Read More

Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19
Industry Insight

Infectious diseases remain a major health threat. The ongoing evolution of viral variants makes it likely that emerging infections will continue to occur – highlighting the need to develop new therapeutic and preventive approaches. Jeff Stein, PhD, President and CEO at Cidara Therapeutics tells Technology Networks more about a novel antiviral strategy they have developed called antiviral conjugates.

Read More

Engineering Innovative CAR T-Cell Therapy Candidates for Cancer
Industry Insight

Technology Networks recently had the pleasure of speaking with Celyad Oncology’s CEO Filippo Petti. In this interview, Petti discusses key immunotherapy advances, highlights the two main CAR T-cell therapy approaches and elaborates on the company’s “off-the-shelf” CAR T cells.

Read More

A New SARS-CoV-2 Descriptive Diagnostic Test – What Makes This Assay Different to Others?
Industry Insight

Clear Labs is a company focused on the latest technologies in molecular testing, machine learning, automation and bioinformatics – it develops fully automated next-generation sequencing and in vitro diagnostics solutions. Technology Networks had the pleasure of speaking with ClearLabs’ CEO Sasan Amini, to learn more about the company’s NGS-based COVID test, Clear Dx™.

Read More

Exploring Plant-Based Bioreactors for Developing COVID-19 Therapeutics and Vaccines
Industry Insight

Technology Networks recently spoke with iBio’s CEO and Chairman of the Board Thomas Isett, to learn more about the company’s efforts to develop a novel COVID-19 therapeutic called ACE2-Fc, as well as two vaccine candidates IBIO-200 and IBIO-201.

Read More

Next-Generation Sequencing: Tracking the Spread and Evolution of SARS-CoV-2
Industry Insight

This article explores how next-generation sequencing (NGS) is being used to help track the spread and evolution of SARS-CoV-2, including pinpoint the different lineages of the virus and identifying patterns of its movement both globally as well as locally.

Read More

Which COVID-19 Vaccines Are in Human Clinical Trials?
Industry Insight

A hub page dedicated to bringing you the latest updates on which COVID-19 vaccines are in human clinical trials.

Read More

A Conversation With Professor Josef Penninger on the Journey to a COVID-19 Therapeutic
Industry Insight

The ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.

Read More

 
Advertisement